BR112023002895A2 - Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas - Google Patents

Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas

Info

Publication number
BR112023002895A2
BR112023002895A2 BR112023002895A BR112023002895A BR112023002895A2 BR 112023002895 A2 BR112023002895 A2 BR 112023002895A2 BR 112023002895 A BR112023002895 A BR 112023002895A BR 112023002895 A BR112023002895 A BR 112023002895A BR 112023002895 A2 BR112023002895 A2 BR 112023002895A2
Authority
BR
Brazil
Prior art keywords
binding proteins
ror1
antibodies
bispecific binding
ror1 antibodies
Prior art date
Application number
BR112023002895A
Other languages
English (en)
Inventor
Gong Shiyong
Ouyang Kedong
Wu Chengbin
Wu Danqing
Wu Xuan
Zhang Rui
Original Assignee
Epimab Biotherapeutics Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimab Biotherapeutics Hk Ltd filed Critical Epimab Biotherapeutics Hk Ltd
Publication of BR112023002895A2 publication Critical patent/BR112023002895A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPOS ANTI-ROR1 E PROTEÍNAS DE LIGAÇÃO BIESPECÍFICAS RELACIONADAS. A presente invenção refere-se a novos anticorpos que reconhecem o receptor órfão tipo tirosina cinase 1 (ROR1), proteínas de ligação ROR1/CD3 biespecíficas, como proteínas de ligação FIT-Ig e MAT-Fab, e o uso dos anticorpos e proteínas de ligação biespecíficas para o tratamento de cânceres hematopoéticos e tumores sólidos.
BR112023002895A 2020-08-24 2021-08-23 Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas BR112023002895A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020110841 2020-08-24
CN2020141398 2020-12-30
PCT/CN2021/114088 WO2022042488A1 (en) 2020-08-24 2021-08-23 Anti-ror1 antibodies and related bispecific binding proteins

Publications (1)

Publication Number Publication Date
BR112023002895A2 true BR112023002895A2 (pt) 2023-03-21

Family

ID=77946069

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002895A BR112023002895A2 (pt) 2020-08-24 2021-08-23 Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas

Country Status (12)

Country Link
US (1) US20240010753A1 (pt)
EP (1) EP4200336A4 (pt)
JP (1) JP2023538945A (pt)
KR (1) KR20230053602A (pt)
CN (2) CN113480656B (pt)
AU (1) AU2021334677A1 (pt)
BR (1) BR112023002895A2 (pt)
CA (1) CA3190117A1 (pt)
IL (1) IL300760A (pt)
MX (1) MX2023002181A (pt)
TW (1) TW202227491A (pt)
WO (1) WO2022042488A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459182B (zh) * 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
BR112019002579A2 (pt) * 2016-08-16 2019-05-21 Epimab Biotherapeutics, Inc. anticorpos biespecíficos fab monovalentes, assimétricos e tandem
CN114539411B (zh) * 2022-04-29 2022-11-11 山东博安生物技术股份有限公司 一种ror1抗体或其抗原结合片段
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2023186100A1 (zh) * 2022-04-02 2023-10-05 山东先声生物制药有限公司 抗ror1的抗体及其用途
WO2024014930A1 (ko) * 2022-07-15 2024-01-18 에이비엘바이오 주식회사 항-ror1 항체, 이를 포함하는 이중특이성 항체, 및 이들의 용도
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024094151A1 (en) * 2022-11-03 2024-05-10 Hansoh Bio Llc Multi-specific antibody and medical use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159847A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
EP3252076B1 (en) * 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN106459182B (zh) * 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
CA2963692A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
CN107847596B (zh) * 2015-05-18 2022-05-31 优瑞科生物技术公司 抗ror1抗体
JP7002446B2 (ja) * 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
EA201891066A1 (ru) * 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
MX2018008934A (es) * 2016-01-22 2019-03-28 Janssen Biotech Inc Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
TW201730212A (zh) * 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
BR112019002579A2 (pt) * 2016-08-16 2019-05-21 Epimab Biotherapeutics, Inc. anticorpos biespecíficos fab monovalentes, assimétricos e tandem
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019204564A1 (en) * 2018-04-18 2019-10-24 Exelixis, Inc. Anti-ror antibody constructs
CN113365660A (zh) * 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
CN111286512A (zh) * 2019-06-05 2020-06-16 南京艾德免疫治疗研究院有限公司 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHODS OF GENERATION AND USE THEREOF
KR20220104783A (ko) * 2019-11-26 2022-07-26 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질

Also Published As

Publication number Publication date
US20240010753A1 (en) 2024-01-11
EP4200336A4 (en) 2024-09-25
KR20230053602A (ko) 2023-04-21
CN113480656A (zh) 2021-10-08
JP2023538945A (ja) 2023-09-12
CN113480656B (zh) 2022-06-03
CA3190117A1 (en) 2022-03-03
TW202227491A (zh) 2022-07-16
EP4200336A1 (en) 2023-06-28
MX2023002181A (es) 2023-03-02
IL300760A (en) 2023-04-01
AU2021334677A1 (en) 2023-03-02
WO2022042488A1 (en) 2022-03-03
CN114085288A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
BR112023002895A2 (pt) Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
SA519410710B1 (ar) أجسام مضادة خاصة لأجل flt3 واستخداماتها
CL2023001092A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
BR112018011058A2 (pt) ?anticorpo, composição, método para tratamento de um indivíduo tendo um câncer, kit de partes, e, uso de um anticorpo ou composição?
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
EA201891066A1 (ru) Антитела к ror1
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
EA201891040A1 (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
PE20210652A1 (es) Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
CO2023000055A2 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
MX2019015349A (es) Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3).
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы